The healthcare sector has been growing swiftly and putting a lot of challenges in front of companies to sustain. In this regard, Propanc Health Group Corp (OTCMKTS:PPCH) has decided to expand its limitations by initiating the second stage of its sought after POP1 research program. It has agreed to enter into a joint research partnership with the University of Jaen for the same cause.
Insights On The Matter:
Propanc Health Group Corp (OTCMKTS:PPCH) is one of the fastest growing healthcare companies in today’s time. It looks after the development of various cut-edge and proprietary treatments for people who are suffering from cancer. With the help of researchers from the University of Jaen, it will look forward to initiating the second stage of the POP1 research program. The primary objective of this joint partnership is to investigate the cellular mechanisms and anti-cancer effects that associated with proenzymes. Reports claim that the proenzyme is one of the highly preferred cancer treatments.
Propanc has its flagship product PRP, which is used for cancer treatments, but it wants to unearth quite a few more patentable options that can be used as the backup compounds to PRP. It’s one of the core objectives of the company entering in this partnership. James Nathanielsz, Chief Executive Officer of Propanc, stated that Jaen, Bath, and Granada Universities played an integral role in the initial research procedure. They all helped the company to discover a few patentable options and how PRP works.
He further added that it wouldn’t have been possible to get huge success in company’s flagship product PRP. Now as the second stage of the POP1 research has initiated, Propanc once again wants to take the help of Jaen University in executing the process successfully. Propanc wants to come up aggressively with the new compounds that can be used in the future. Joint research agreement will help the company in doing so.